15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data

R Baldassano, Harland S. Winter, M Dubinsky et al.|Journal of Crohn s and Colitis|2013

Cited by 3